SCHEMBL3017315

SCHEMBL3017315

Cc1cccc(C)c1Cc1csc(N2CCC(S(=O)(=O)c3ccc(CBr)cc3)CC2)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.36
DNM1L O00429 8/20 0.33
HTR2A P28223 3/20 0.33
LMNA P02545 2/20 0.33
KMT2A Q03164 2/20 0.32
MEN1 O00255 1/20 0.32
MAPK1 P28482 1/20 0.32
KCNH2 Q12809 2/20 0.32
HTR2C P28335 1/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
MAPT P10636 2/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP1A2 P05177 1/20 0.31
POLB P06746 1/20 0.31
CYP2C9 P11712 1/20 0.31
HPGD P15428 1/20 0.31
CYP2C19 P33261 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3022020 0.92 DNM1L (0.36) GBA1DNM1LKMT2ANPC1RAB9A
SCHEMBL3000622 0.90 RAB9A (0.37) GBA1DNM1LHTR2ALMNAKMT2A
SCHEMBL3013813 0.90 GBA1 (0.44) GBA1DNM1LLMNAKMT2AMEN1
SCHEMBL3013464 0.90 GBA1 (0.35) GBA1DNM1LHTR2ALMNAKMT2A
SCHEMBL3017247 0.90 GBA1 (0.38) GBA1DNM1LHTR2ALMNAKMT2A
SCHEMBL3007172 0.89 MAPT (0.41) GBA1HTR2ALMNAKMT2AMEN1
SCHEMBL3023007 0.89 MEN1 (0.38) GBA1DNM1LHTR2ALMNAKMT2A
SCHEMBL3015039 0.87 GBA1 (0.42) GBA1DNM1LHTR2ALMNAKMT2A
SCHEMBL3007186 0.87 GBA1 (0.37) GBA1DNM1LHTR2AKMT2AKCNH2
SCHEMBL3016829 0.87 DNM1L (0.35) GBA1DNM1LKMT2ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA GBA1 4/4885DNM1L 180/4885HTR2A 752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.